Harpreet K Dhaliwal1, Barbara S Hoeroldt2, Asha K Dube3, Elaine McFarlane1, James C E Underwood4, Mohammed A Karajeh1, Dermot Gleeson1. 1. Liver Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK. 2. Department of Gastroenterology, Rotherham General Hospital, Rotherham, UK. 3. Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 4. Academic Unit of Pathology, University of Sheffield, Sheffield, UK.
Abstract
OBJECTIVES: Biochemical remission is widely considered a satisfactory treatment end point in autoimmune hepatitis (AIH). The significance of persisting histological activity despite biochemical remission is unknown. We aimed to assess the frequency and prognostic significance of persisting histological inflammation in patients with AIH who had achieved biochemical remission with treatment. METHODS: We studied 120 patients (median age at diagnosis 57 years; 81% female) with AIH by International Criteria (59% definite), who received immunosuppressive treatment and underwent a follow-up liver biopsy after at least 6 months of sustained biochemical remission (defined as normal serum ALT and globulin). RESULTS: Fifty-five patients (46%) had persisting histological activity (Ishak histological activity index (HAI) ≥4). These patients had higher serum ALT (24 vs. 18 IU/l, P=0.003) and AST (27 vs. 23 IU/l, P=0.03) at the time of follow-up biopsy, compared with patients who achieved histological remission (HAI ≤3). They had less frequent regression of fibrosis on follow-up biopsy compared with those achieving histological remission (32 vs. 60%, P=0.004) and had excess mortality (standardized mortality ratio 1.4 vs. 0.7, P<0.05). The excess mortality was due to liver disease. On multivariate analysis, persisting histological activity was independently associated with all-cause death/transplantation (HR 3.1 (95% CI 1.2-8.1); P=0.02); an association with liver-related death/transplantation fell short of significance (HR 9.7 (95% CI 0.84-111.6; P=0.07). CONCLUSIONS: Persisting histological activity, despite biochemical remission, is frequent in patients with treated AIH and is associated with lower rates of fibrosis regression and reduced long-term survival.
OBJECTIVES: Biochemical remission is widely considered a satisfactory treatment end point in autoimmune hepatitis (AIH). The significance of persisting histological activity despite biochemical remission is unknown. We aimed to assess the frequency and prognostic significance of persisting histological inflammation in patients with AIH who had achieved biochemical remission with treatment. METHODS: We studied 120 patients (median age at diagnosis 57 years; 81% female) with AIH by International Criteria (59% definite), who received immunosuppressive treatment and underwent a follow-up liver biopsy after at least 6 months of sustained biochemical remission (defined as normal serum ALT and globulin). RESULTS: Fifty-five patients (46%) had persisting histological activity (Ishak histological activity index (HAI) ≥4). These patients had higher serum ALT (24 vs. 18 IU/l, P=0.003) and AST (27 vs. 23 IU/l, P=0.03) at the time of follow-up biopsy, compared with patients who achieved histological remission (HAI ≤3). They had less frequent regression of fibrosis on follow-up biopsy compared with those achieving histological remission (32 vs. 60%, P=0.004) and had excess mortality (standardized mortality ratio 1.4 vs. 0.7, P<0.05). The excess mortality was due to liver disease. On multivariate analysis, persisting histological activity was independently associated with all-cause death/transplantation (HR 3.1 (95% CI 1.2-8.1); P=0.02); an association with liver-related death/transplantation fell short of significance (HR 9.7 (95% CI 0.84-111.6; P=0.07). CONCLUSIONS: Persisting histological activity, despite biochemical remission, is frequent in patients with treated AIH and is associated with lower rates of fibrosis regression and reduced long-term survival.
Authors: Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya Journal: J Hepatol Date: 1999-11 Impact factor: 25.083
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Cumali Efe; Haider Al Taii; Henriette Ytting; Niklas Aehling; Rahima A Bhanji; Hannes Hagström; Tugrul Purnak; Luigi Muratori; Mårten Werner; Paolo Muratori; Daniel Klintman; Thomas D Schiano; Aldo J Montano-Loza; Thomas Berg; Fin Stolze Larsen; Naim Alkhouri; Ersan Ozaslan; Michael A Heneghan; Eric M Yoshida; Staffan Wahlin Journal: Dig Dis Sci Date: 2018-03-22 Impact factor: 3.199
Authors: Simon D Lytton; Marcin Osiecki; Bożena Cukrowska; Aldona Wierzbicka; Maria Goliszek; Piotr Socha; Wojciech Janczyk; Dilek Dayanakli; Dieter Abendroth; Sabine Kramp; Kai Fechner; Thomas Scheper; Michael Mahler; Chelsea Bentow; Dimietrios Bogdanos; Dietmar Fuchs; Marek Woynarowski Journal: Immunol Res Date: 2019-02 Impact factor: 2.829
Authors: Katherine Arndtz; Elizabeth Shumbayawonda; James Hodson; Peter J Eddowes; Andrea Dennis; Helena Thomaides-Brears; Sofia Mouchti; Matt D Kelly; Rajarshi Banerjee; Stefan Neubauer; Gideon M Hirschfield Journal: Hepatol Commun Date: 2021-02-23